Literature DB >> 21052827

Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro.

Anastasia Bologov1, Mikhal Gafni, Ora Keren, Yosef Sarne.   

Abstract

Either protective or toxic effects of cannabinoids on cell survival have been reported extensively in the literature; however, the factors that determine the direction of the effect are still obscured. In this study we have used the neuroblastoma cell line N18TG2 that expresses CB1 cannabinoid receptors to investigate several factors that may determine the consequences of exposure to cannabinoid agonists. Cells that were grown under optimal, stressful, or differentiating conditions were exposed to cannabinoid agonists and then assayed for cell viability by measuring MTT, LDH, and caspase-3 activity. Various cannabinoid agonists (CP 55,940, ∆9-THC, HU-210, and WIN 55,212-2) failed to affect cell viability when the cells were grown under optimal conditions. On the other hand, the same agonists significantly reduced cell viability when the cells were grown under stressful conditions (glucose- and serum-free medium), while enhancing the viability of cells grown in differentiation medium (0.5% serum and 1.5% DMSO). The toxic/protective profile was not dependent on the type or the concentration of the cannabinoid agonist that was applied. The cannabinoid agonist CP 55,940 similarly affected the non-neuronal HEK-293 cells that were grown under stressful conditions only when they expressed CB1 receptors. Our results shed light on the conflicting reports regarding the protective or toxic effects of cannabinoids in vitro and indicate that cannabinoids may activate different intracellular signaling mechanisms, depending on the state of the cell, thus leading to different physiological consequences.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21052827     DOI: 10.1007/s10571-010-9604-y

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  43 in total

1.  Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.

Authors:  M E Abood; G Rizvi; N Sallapudi; S D McAllister
Journal:  Neurosci Lett       Date:  2001-08-31       Impact factor: 3.046

2.  Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism.

Authors:  M P Caulfield; D A Brown
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

Review 3.  Pharmacology of cannabinoid receptors.

Authors:  A C Howlett
Journal:  Annu Rev Pharmacol Toxicol       Date:  1995       Impact factor: 13.820

Review 4.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

5.  Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions.

Authors:  Somnath Mukhopadhyay; Allyn C Howlett
Journal:  Mol Pharmacol       Date:  2005-03-04       Impact factor: 4.436

6.  Cannabinoid receptor as a novel target for the treatment of prostate cancer.

Authors:  Sami Sarfaraz; Farrukh Afaq; Vaqar M Adhami; Hasan Mukhtar
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

Review 7.  Mechanisms of control of neuron survival by the endocannabinoid system.

Authors:  Ismael Galve-Roperh; Tania Aguado; Javier Palazuelos; Manuel Guzmán
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

8.  Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation.

Authors:  Diane Gesty-Palmer; Minyong Chen; Eric Reiter; Seungkirl Ahn; Christopher D Nelson; Shuntai Wang; Allen E Eckhardt; Conrad L Cowan; Robert F Spurney; Louis M Luttrell; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

9.  Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants.

Authors:  A J Hampson; M Grimaldi; J Axelrod; D Wink
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.

Authors:  K A Berg; S Maayani; J Goldfarb; C Scaramellini; P Leff; W P Clarke
Journal:  Mol Pharmacol       Date:  1998-07       Impact factor: 4.436

View more
  4 in total

1.  Carbon monoxide incompletely prevents isoflurane-induced defects in murine neurodevelopment.

Authors:  Li Wang; Aili Wang; William W Supplee; Kayla Koffler; Ying Cheng; Zenaide M N Quezado; Richard J Levy
Journal:  Neurotoxicol Teratol       Date:  2017-01-26       Impact factor: 3.763

Review 2.  The dual neuroprotective-neurotoxic profile of cannabinoid drugs.

Authors:  Yosef Sarne; Fadi Asaf; Miriam Fishbein; Mikhal Gafni; Ora Keren
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

Review 3.  Carbon monoxide and anesthesia-induced neurotoxicity.

Authors:  Richard J Levy
Journal:  Neurotoxicol Teratol       Date:  2016-09-09       Impact factor: 3.763

4.  The Cannabinoid CB1/CB2 Agonist WIN55212.2 Promotes Oligodendrocyte Differentiation In Vitro and Neuroprotection During the Cuprizone-Induced Central Nervous System Demyelination.

Authors:  Jordi Tomas-Roig; Oliver Wirths; Gabriela Salinas-Riester; Ursula Havemann-Reinecke
Journal:  CNS Neurosci Ther       Date:  2016-02-04       Impact factor: 5.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.